Veteran drug could prevent Covid lung damage, study shows
Fenofibrate (Tricor) could potentially turn Covid from a devastating disease into a far more manageable form of a respiratory cold.
December 23, 2020, 10:59 am
Healthcare workers at work at the coronavirus ward of Shaare Zedek Medical Center in Jerusalem. Photo by Olivier Fitoussi/Flash90
Initial data from a new study shows that a well-established drug could prevent lung damage in Covid-19 patients, potentially reducing its severity and mortality rates and turning it from a devastating disease into a far more manageable form of a respiratory cold.
Back in July, a study led by the Hebrew University of Jerusalem demonstrated that Covid-19 inhibits the effective breakdown in lungs and that the resulting buildup of fats in lung cells play a critical role in the deterioration of patients’ condition.